PE-22-28 Dosage Guide, Benefits & Side Effects

Because no controlled human trials have been published, there is no verified human side-effect profile for PE-22-28. Anecdotal and vendor reports mention mild, transient issues such as injection-site redness, drowsiness, or headache, particularly with rapid dose increases, but these are not confirmed by peer-reviewed clinical data. Preclinical studies have not reported significant organ toxicity, but this does not establish human safety.

As with most research peptides, lyophilized (freeze-dried) PE-22-28 is typically stored frozen (around -20°C) and protected from light and moisture until use. It is generally reconstituted with bacteriostatic water or sterile saline and, once reconstituted, kept refrigerated (2-8°C) and used within a few weeks, since peptide integrity degrades over time at higher temperatures or with repeated freeze-thaw cycles. Always follow the specific manufacturer's documentation, as stability data varies by supplier and formulation.

PE-22-28 is not an FDA-approved drug and has no approved therapeutic indication. It is sold by research chemical suppliers labeled "for laboratory/research use only, not for human consumption," meaning it has not been evaluated for human safety, purity, or dosing by regulatory agencies. Buyers should be aware that product purity and identity are not independently guaranteed across vendors, and using it outside of a licensed research setting carries unknown risk.

PE-22-28 is a shortened, chemically optimized fragment of spadin designed to retain or improve TREK-1 channel binding while offering greater resistance to enzymatic degradation in the body. Research comparing the two reports substantially higher potency and longer plasma stability for PE-22-28 relative to full-length spadin, which is why it has become the more commonly referenced compound in newer TREK-1 research.